drug · small molecule
regorafenib
Marketedupdated 5mo agoby Bayer AG🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 30 investigational indications.
targets
Discoidin domain-containing receptor 2Ephrin type-A receptor 2Fibroblast growth factor receptor 2Mitogen-activated protein kinase 11Platelet-derived growth factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying regorafenib
- phase2Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- phase3A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
- phase3Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
- phase2Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
- phase3RegoNivo vs Standard of Care Chemotherapy in AGOC
- phase3Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- phase3A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 2, 2030
~3.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Jul 9, 2032compositionUS 9957232
- Apr 8, 2031formulationUS 94581074.5y
- Feb 16, 2031compositionUS 86375534.4y
- Jun 2, 2030method-of-use (U-1506)US 86801243.7y
News(1)
- FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancerThe FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor in combination with Roche’s Tecentriq for the treatment of metastatic colorectal cancer.fiercebiotech · 22d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that